The U.S. Food and Drug Administration recently approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis). Technivie in combination with ribavirin is the first drug that has demonstrated safety and efficacy to treat genotype 4 HCV infections without the need for co-administration of interferon, an FDA-approved drug also used to treat HCV infection.|
IDSA offers two email services to help members stay informed of updates from FDA and the Centers for Disease Control and Prevention (CDC). Content includes a range of topics, including drug warnings, recalls, and outbreak investigations. Recent alerts have included:
Gilenya (fingolimod): Drug Safety Communication - FDA Warns About Cases of Rare Brain Infection (August 4, 2015)
Kaletra (lopinavir/ritonavir) product labeling updated (June 30, 2015)
Clinical Considerations for the Evaluation of Ill Travelers from Liberia to the United States (June 24, 2015)
Updated Information and Guidelines for Evaluation of Patients for MERS-CoV Infection (June 12, 2015)
IDSA members can sign up for these services online. (To subscribe, check the appropriate boxes to receive CDC’s Health Alert Network [HAN] messages and/or alerts from FDA, and provide your email address and name where indicated.)
Is Your Facility Experiencing Antibiotic Shortages?
IDSA members are urged to report drug shortages directly to FDA and to copy IDSA staff at email@example.com.
< Previous Article | Next Article >